Figure 2.
Unbound and total edoxaban and D21-2393 plasma concentrations on day 6 after the last dose of edoxaban with different andexanet alfa dosing regimens. (A) Unbound edoxaban. (B) Unbound D21-2393. (C) Total edoxaban (lower left panel) and total D21-2393 (lower right panel). Andexanet alfa was dosed at 3 hours (cohorts 1-2) or 5 hours (cohort 3) after the last dose of edoxaban with the 600-mg bolus (cohort 1), 800-mg bolus plus 8 mg/min × 1-hour infusion (cohort 2), and 800-mg bolus (cohort 3), respectively.

Unbound and total edoxaban and D21-2393 plasma concentrations on day 6 after the last dose of edoxaban with different andexanet alfa dosing regimens. (A) Unbound edoxaban. (B) Unbound D21-2393. (C) Total edoxaban (lower left panel) and total D21-2393 (lower right panel). Andexanet alfa was dosed at 3 hours (cohorts 1-2) or 5 hours (cohort 3) after the last dose of edoxaban with the 600-mg bolus (cohort 1), 800-mg bolus plus 8 mg/min × 1-hour infusion (cohort 2), and 800-mg bolus (cohort 3), respectively.

Close Modal

or Create an Account

Close Modal
Close Modal